Ｐａｇｅ 827256 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼you fuck a cookhous FluegoNadaged 13/9/29(日) 1:55 ─────────────────────────────────────── ■題名 ： you fuck a cookhous ■名前 ： FluegoNadaged <Sitysheestegw@allairmaxsaleoutlet.us> ■日付 ： 13/9/29(日) 1:55 ■Ｗｅｂ ： http://www.coach-outlets-discount.com/ -------------------------------------------------------------------------
| Buried within the オロビアンコ バッグ メンズ Dealing that progressively Hollywood sensations are wearing boots from UGG Australia オロビアンコ ベルト プレゼント Dealing that progressively Hollywood sensations are wearing boots from UGG Australia オロビアンコ 長財布 ラウンド Dealing that progressively Hollywood sensations are wearing boots from UGG Australia オロビアンコ アウトレット 店舗 Generic Drugs Battlefield Generic pharmaceuticals as an industry has extremely favorable demand dynamics. Various secular trends are converging that will advantage オロビアンコ バッグ メンズ this market. are aggressively in search of out techniques to lower skyrocketing well being care fees. Since オロビアンコ バッグ メンズ マルイ 1960, healthcare spending has expanded from 5% of GDP to over 17% in 2009. Prescription drugs account for about 10% of all healthcare spending, so this is an obvious region to target. Generic versions of branded drugs generally sell for half to onethird from the cost. Given this, well being care payers have often オロビアンコ ベルト 日本製 restricted reimbursement to generic versions of particular therapies, raising the demand for them. From 2004 to 2009, generics marketplace share rose from 56% of prescription dollars to practically http://xn--cckp2a1j7eob1457jm0f.tooth-body.com/ 75%. Among the list of 2010 healthcare bill's principal goals was to enhance access to the roughly 15% of Americans with no well being insurance coverage. By eliminating insurance coverage denials as a result of current conditions, preventing the dropping coverage for sick sufferers, and offering incentives to smaller companies delivering coverage, extra folks will be insured and much more people might be http://xn--cckp2a2a8irdud5bc.lwvlosangeles.com/ in a position to purchase prescriptions. Ultimately, there is certainly オロビアンコ 時計 評判 demographics. The number of Americans more than 65 will raise 3% a year over the next ten http://xn--cckp2a1j7eob0556cok1a.tooth-body.com/ years, an further 14 million people entering Medicare. Naturally, older people in general demand much more medical care, which includes prescription drugs. Put it all together plus the image is bright for generics. This trend is set to accelerate more than the next couple of years. 6 オロビアンコ ボディバッグ ジャコミーノ with the major 20 most desirable オロビアンコ ベルト 日本製 promoting branded drugs are set to drop patent protection in 2011 and 2012, with two added オロビアンコ アウトレット drugs that have more than a billion dollars a year in sales expiring in 2012. That is an astounding $43 billion dollars in branded drug sales that should be open to generic competitors. So it would look to become a slam dunk to advise generics maker Par Pharmaceuticals (PRX) as an desirable Magic Formula stock. Par generates 90% of its sales from generics, and all of its profits. Par includes a two pronged approach. First, it targets smaller and less competitive drugs to create. By doing this, the business can beat its competitors in filing abbreviated new drug applications (ANDAs) with the FDA, which supplies 180 days of advertising and marketing exclusivity right after the branded drug goes off patent. That is massive inside the generics organization windfalls from highmargin sales in these 180 days can normally create many "normal years" worth of profits. This provides Par a slight competitive advantage and also makes it possible for them to charge a little more. Around the downside, it commonly calls for Par to pay royalties towards the branded maker. Par will not be fairly the slam dunk it would look オロビアンコ 時計 TICTAC to become. The enterprise just isn't targeting any from the aforementioned blockbuster drugs there's just an excessive amount of competitors http://xn--cckp2a1j7eob5289c317a.tooth-body.com/ for them. And that's one of several massive challenges with this industry. Scale is hugely vital http://xn--cckp2a1j7eob5289c317a.lwvlosangeles.com/ to creating economical gross margins and keeping the legal talent required to succeed in patent challenges. At just $1 billion in sales, Par pales in comparison to Teva (TEVA) ($16 billion), Sandoz (NVS) ($9 billion), or Mylan (MYL) ($5.four billion), to not mention numerous similar sized competitors. After exclusivity periods end, competitors commonly floods into the marketplace, driving down sales and margins. An excellent example オロビアンコ ベルト プレゼント of that is Par's biggest item: a generic version of AstraZeneca's (AZN) Toprol XL (metroprolol). Early on, competitors was limited, and then there was no competitors in initially 2 quarters of 2009, driving a 100% sales enhance オロビアンコ バッグ メンズ ボストン more than 2008. Still, Watson (WPI) came in to the industry in late 2009, and considering that オロビアンコ 時計 ベルト 交換 then an Indian generics firm has also entered. Pricing and volumes suffered. In the justreported first quarter of 2011, metroprolol sales fell 65% over the prior year! Competitors may also lead to cheating. In Q1, Par recorded a $190 million charge to settle claims on the enterprise オロビアンコ バッグ トート overinflating the wholesale costs シップス オロビアンコ レディース they report to insurers. The alleged scheme is that Par (and competitors) charge less to pharmacies and report larger promoting costs to insurers. Due to the fact the insurer is reimbursing the pharmacy at a greater rate than they pay for the drugs, it really is a nice purpose オロビアンコ ベルト プレゼント for the pharmacy to decide on Par's solution more than a competitor's. This can be a troublesome organization to value. It is tough to predict the impact of new competitors on existing sales, and if Par is going to be in a position to win exclusivity. The firm reports 12 firsttofile ANDAs, 2 prospective firsttomarket possibilities, and program five to 7 new ANDA filings a year more than the subsequent handful of years. Revenues and profitability are extremely boomandbust. Par also has a branded drug unit called Strativa, but so far this unit has been unprofitable, and probably will stay so for several years. You will find a range of possibilities for Par, but a median case puts a fair value http://xn--cckp2a1j7eob1457jm0f.lwvlosangeles.com/ of about $40 around the stock. Given that this can be a especially uncertain calculation, MagicDiligence features a neutral opinion. There can be better Magic Formula stocks to think about. |